To include your compound in the COVID-19 Resource Center, submit it here.

Cytokinetics begins Phase III CVOT trial of omecamtiv mecarbil

Cytokinetics Inc. (NASDAQ:CYTK) began the Phase III GALACTIC-HF cardiovascular outcomes trial (CVOT) trial evaluating twice-daily oral omecamtiv mercarbil

Read the full 184 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE